评论
打印
Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did.
制药商美国渤健公司和日本卫材药业表示，在两家公司进行的一项大型人体研究中，他们的实验药物lecanemab减缓了阿尔茨海默病患者的疾病过程。
The results could mean a rare victory in a field filled with failed experiments to find an effective treatment for the disease.
这一结果可能意味着在一个充满了失败实验的领域取得了罕见的胜利，做这些实验的目的是找到治疗这种疾病的有效方法。
The companies said early results showed that the treatment reduced cognitive loss by 27 percent when compared to a placebo, an inactive substance.
两家公司表示，早期结果显示，与安慰剂（一种非活性物质）相比，这种治疗方法使得认知衰退幅度减缓了27%。
The 18-month-long study involved 1,800 subjects.
这项长达18个月的研究涉及1800名受试者。
All had been identified with early-stage Alzheimer’s.
所有人都是早期阿尔茨海默病患者。
The patients were measured for mental decline and their ability to do daily activities like putting on clothes and feeding themselves.
研究人员对这些患者的智力衰退程度以及他们自己穿衣服和吃饭等日常活动的能力进行了测量。
Dr. Jeff Cummings is the director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada Las Vegas.
杰夫·卡明斯博士是内华达大学拉斯维加斯分校钱伯斯-格伦迪转化神经科学中心的主任。
The expert told Reuters, "If you can slow a disease by almost 30 percent, that's fantastic.”
这位专家告诉路透社，“如果你能将一种疾病减缓近30%，那就太棒了。”
Expert Ronald Petersen also praised the findings.
专家罗纳德·彼得森也称赞了这一研究结果。
"It's not a huge effect, but it's a positive effect,” he said.
他说：“这不是一个巨大的影响，但却是一个积极的影响。”
Peterson directs the Mayo Clinic Alzheimer's Disease Research Center in Rochester, Minnesota.
彼得森是明尼苏达州罗切斯特市梅奥诊所阿尔茨海默病研究中心的负责人。
A statement from the Alzheimer’s Association called the findings the most hopeful to date for possible treatments of the disease causes.
阿尔茨海默病协会的一份声明称，这一研究结果是迄今为止针对该疾病病因最有希望的可能治疗方法。
Eisai said it would discuss the full results from the study in late November.
日本卫材药业表示，其将在11月下旬讨论这项研究的全部结果。
It also plans to publish findings in a medical publication.
它还计划在一本医学出版物上发表研究结果。
And the company said it is seeking quick approval for the drug in the United States., Japan and Europe by early next year.
该公司表示，它正在寻求在明年年初之前快速获得该药物在美国、日本和欧洲上市的批准。
The World Health Organization estimates that 50 million people around the world have dementia.
世界卫生组织估计，全球有5000万人患有痴呆症。
Alzheimer's disease might be the cause of 60 to 70 percent of dementia cases.
阿尔茨海默病可能是60%到70%的痴呆症病例的病因。
Alzheimer’s slowly attacks areas of the brain needed for memory, reasoning, communication and basic, daily tasks.
阿尔茨海默病会慢慢攻击大脑中负责记忆、推理、沟通和基本日常任务的区域。
There is no known cure for the disease.
目前这种病还没有已知的治疗方法。
And long-standing treatments on the market just manage symptoms.
而市场上长期存在的治疗方法只能控制症状。
Last year, Biogen’s aduhelm became the first new Alzheimer’s drug introduced in 20 years.
去年，美国渤健公司的阿杜那单抗成为20年来推出的第一种治疗阿尔茨海默病的新药。
Given weak evidence of its effectiveness and the high prices, doctors and insurers have not given the treatment to patients.
由于缺乏证据证明其有效性和高昂的价格，医生和保险公司没有向患者提供这种治疗方法。
The beta-amyloid protein is involved in the development of Alzheimer’s.
β淀粉样蛋白与阿尔茨海默症的发展有关。
Both lecanemab and aduhelm aim to remove the protein from the brain.
lecanemab和aduhelm的目标都是将这种蛋白质从大脑中去除。
But lecanemab tries to clear the protein before it could form a hard cover on the brain.
但lecanemab试图在这种蛋白质在大脑上形成硬块之前将其清除。
Another drugmaker, Eli Lilly, said it is also developing a possible treatment, donanemab, that targets the protein.
另一家制药商礼来公司表示，它也在开发一种可能的治疗方法，即针对这种蛋白质的多纳单抗。
The race to slow the progression of Alzheimer's comes as the number of Americans living with the disease is expected to double to 13 million by 2050, the Alzheimer's Association said.
阿尔茨海默病协会表示，在竞相减缓阿尔茨海默病患者的疾病过程的同时，到2050年，美国患有阿尔茨海默病的人数预计将会翻一番，达到1300万人。
Around the world, Alzheimer's Disease International said the number of disease cases could reach well over 100 million people by 2050 if no effective treatment is found.
国际阿尔茨海默病协会表示，如果找不到有效的治疗方法，到2050年，全球阿尔茨海默病患者的数量可能会超过1亿人。
I'm Caty Weaver.
凯蒂·韦弗为您播报。
译文为可可英语翻译，未经授权请勿转载！
